With this collaboration, Respiree's patient
monitoring solution will be made available for healthcare
professionals in APAC through a pilot program
using Roche's blood glucose monitoring
system. The goal is to simplify clinical workflows
and augment diagnostic and monitoring capabilities, leading to
improved patient outcomes.
SINGAPORE, Sept. 17,
2024 /PRNewswire/ -- Existing patient monitoring workflows
often rely on nurses managing patients from centralized
workstations, monitoring vitals and biomarkers at different
intervals, and manually collecting vitals. This process can be
inefficient, especially with limited workstations, multiple
workflows, increased patient volumes, and nursing shortages.
By the first quarter of 2025, Respiree will team
up with Roche to launch pilot programs across APAC that offer a
simplified approach to patient monitoring by combining Roche's
cobas® pulse system with Respiree's vital sign monitoring. The
solution is also expected in future to integrate machine learning
models that predict clinical deterioration using historical data
with risk scores at the bedside.
The cobas® pulse system, a point of care device,
equipped with digital health applications based on the Android
operating system allows for real-time administration and
visualization, eliminating the need for centralized workstations.
Respiree's solution measures multiple biometrics, including pulse
rate, oxygen saturation, respiratory rate, temperature, tidal
depth, inhalation-to-exhalation ratios, and has the capability to
input blood pressure measurements.
With the use of Respiree and cobas® pulse
solutions, healthcare professionals can register patients to
Respiree's connected devices in real-time, monitor historical data
and potential deterioration directly at the patient's bedside
without needing to return to workstations or medical carts, as well
as simultaneously measure vital signs and blood sugar. They can
annotate clinical notes on the Respiree solution in the cobas®
pulse system.
"The use of Respiree with the cobas® pulse system
has tremendous potential to enhance clinical workflows. Nurses can
administer devices and view historical vitals in real-time without
the need for centralized workstations, providing immediate bedside
insights into patient progress. Additionally, nurses can automate
the extraction and measurement of vitals from connected devices
almost instantaneously, removing the need for manual scanning and
measurements," says Dr. Gurpreet
Singh, CEO and Founder of Respiree.
About Respiree
Respiree is an AI/ML health tech company building
clinically-validated AI for managing disease progression. Respiree
is CE marked and has received regulatory clearances from the
Therapeutic Goods Administration and the United States Food and
Drug Administration (FDA).
Photo -
https://mma.prnewswire.com/media/2507323/Press_Release.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/respiree-teams-up-with-roche-diagnostics-in-apac-to-introduce-a-new-simplified-way-of-hospital-patient-monitoring-302250251.html